Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies
Crossref DOI link: https://doi.org/10.2337/dc15-1643
Published Online: 2015-12-17
Published Print: 2016-07-01
Update policy: https://doi.org/10.2337/ada-journal-policies
Kazda, Christof M.
Ding, Ying
Kelly, Ronan P.
Garhyan, Parag
Shi, Chunxue
Lim, Chay Ngee
Fu, Haoda
Watson, David E.
Lewin, Andrew J.
Landschulz, William H.
Deeg, Mark A.
Moller, David E.
Hardy, Thomas A.
